Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy

References

• Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol. 1997;81(11):962–964. doi:10.1136/bjo.81.11.962
   PubMed Web of Science ®Google Scholar
• van Haalen FM, van Dijk EHC, Dekkers OM, et al. Cushing’s syndrome and hypothalamic-pituitary-adrenal axis hyperactivity in chronic central serous chorioretinopathy. Front Endocrinol (Lausanne). 2018;9:39. doi:10.3389/fendo.2018.00039
   PubMed Web of Science ®Google Scholar
• Eymard P, Gerardy M, Bouys L, et al. Choroidal imaging in patients with Cushing syndrome. Acta Ophthalmol. 2021;99(5):533–537. doi:10.1111/aos.14664
   PubMed Web of Science ®Google Scholar
• Wang E, Chen S, Yang H, Yang J, Li Y, Chen Y. Choroidal thickening and pachychoroid in Cushing syndrome: correlation with endogenous cortisol level. Retina. 2019;39(2):408–414. doi:10.1097/IAE.0000000000001956
   PubMed Web of Science ®Google Scholar
• Karaca C, Karaca Z, Kahraman N, Sirakaya E, Oner A, Mirza GE. Is there a role of ACTH in increased choroidal thickness in Cushing syndrome? Retina. 2017;37(3):536–543. doi:10.1097/IAE.0000000000001198
   PubMed Web of Science ®Google Scholar
• Abalem MF, Machado MC, Santos HN, et al. Choroidal and retinal abnormalities by optical coherence tomography in endogenous Cushing’s syndrome. Front Endocrinol (Lausanne). 2016;7:154. doi:10.3389/fendo.2016.00154
   PubMed Web of Science ®Google Scholar
• Ji Y, Li M, Zhang X, et al. Poor sleep quality is the risk factor for central serous chorioretinopathy. J Ophthalmol. 2018;2018:9450297. doi:10.1155/2018/9450297
   PubMed Web of Science ®Google Scholar
• Gawecki M, Jaszczuk-Maciejewska A, Jurska-Jasko A, et al. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol. 2019;19(1):160. doi:10.1186/s12886-019-1171-5
   PubMed Web of Science ®Google Scholar
• Baran NV, Gurlu VP, Esgin H. Long-term macular function in eyes with central serous chorioretinopathy. Clin Exp Ophthalmol. 2005;33(4):369–372. doi:10.1111/j.1442-9071.2005.01027.x
   PubMed Web of Science ®Google Scholar
• Petkovsek DS, Cherfan DG, Conti FF, et al. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Br J Ophthalmol. 2020;104(2):182–187. doi:10.1136/bjophthalmol-2019-314047
   PubMed Web of Science ®Google Scholar
• Lotery A, Sivaprasad S, O’Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10220):294–303. doi:10.1016/S0140-6736(19)32981-2
   PubMed Web of Science ®Google Scholar
• Ciloglu E, Unal F, Dogan NC. The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. Graefes Arch Clin Exp Ophthalmol. 2018;256(6):1111–1116. doi:10.1007/s00417-018-3985-x
   PubMed Web of Science ®Google Scholar
• Gergely R, Kovacs I, Schneider M, et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina. 2017;37(6):1084–1091. doi:10.1097/IAE.0000000000001303
   PubMed Web of Science ®Google Scholar
• Odermatt A, Atanasov AG. Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids. 2009;74(2):163–171. doi:10.1016/j.steroids.2008.10.010
   PubMed Web of Science ®Google Scholar
• Shalet S, Mukherjee A. Pharmacological treatment of hypercortisolism. Curr Opin Endocrinol Diabetes Obes. 2008;15(3):234–238. doi:10.1097/MED.0b013e3282fc7025
   PubMedGoogle Scholar
• Nagappa M, Liao P, Wong J, et al. Validation of the STOP-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis. PLoS One. 2015;10(12):e0143697. doi:10.1371/journal.pone.0143697
   PubMed Web of Science ®Google Scholar
• Unlu C, Erdogan G, Aydogan T, et al. Intravitreal bevacizumab for treatment of central serous chorioretinopathy. J Ophthalmic Vis Res. 2016;11(1):61–65. doi:10.4103/2008-322X.180700
   PubMedGoogle Scholar
• Lu HQ, Wang EQ, Zhang T, Chen YX. Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis. Eye. 2016;30(1):15–22. doi:10.1038/eye.2015.208
   PubMed Web of Science ®Google Scholar
• Breukink MB, Dingemans AJ, den Hollander AI, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol. 2017;11:39–46. doi:10.2147/OPTH.S115685
   PubMed Web of Science ®Google Scholar
• van Rijssen TJ, van Dijk EHC, Scholz P, et al. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. Acta Ophthalmol. 2021;99(7):805–811. doi:10.1111/aos.14775
   PubMed Web of Science ®Google Scholar
• Bansal V, El Asmar N, Selman WR, Arafah BM. Pitfalls in the diagnosis and management of Cushing’s syndrome. Neurosurg Focus. 2015;38(2):E4. doi:10.3171/2014.11.FOCUS14704
   PubMed Web of Science ®Google Scholar
• Ozkaya A, Alkin Z, Ozveren M, et al. The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study. Eye. 2016;30(7):1005–1010. doi:10.1038/eye.2016.79
   PubMed Web of Science ®Google Scholar
• van Rijssen TJ, van Dijk EHC, Tsonaka R, et al. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol. 2022;233:101–110. doi:10.1016/j.ajo.2021.06.020
   PubMed Web of Science ®Google Scholar
• Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92(8):e594–e601. doi:10.1111/aos.12482
   PubMed Web of Science ®Google Scholar
• Lai FH, Ng DS, Bakthavatsalam M, et al. A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2016;170:91–99. doi:10.1016/j.ajo.2016.07.026
   PubMed Web of Science ®Google Scholar
• Schwartz R, Habot-Wilner Z, Martinez MR, et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017;95(7):e610–e618. doi:10.1111/aos.13491
   PubMed Web of Science ®Google Scholar
• Karahan E, Zengin MO, Aydin R, et al. Correlation of choroidal thickness with serum cortisol level. Clin Exp Optom. 2015;98(4):362–365. doi:10.1111/cxo.12254
   PubMed Web of Science ®Google Scholar
• Perogamvros I, Ray DW, Trainer PJ. Regulation of cortisol bioavailability–effects on hormone measurement and action. Nat Rev Endocrinol. 2012;8(12):717–727. doi:10.1038/nrendo.2012.134
   PubMed Web of Science ®Google Scholar
• Golshahi A, Klingmuller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol. 2010;88(5):576–581. doi:10.1111/j.1755-3768.2008.01467.x
   PubMed Web of Science ®Google Scholar
• Meyerle CB, Freund KB, Bhatnagar P, et al. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007;27(7):943–946. doi:10.1097/IAE.0b013e318050ca69
   PubMed Web of Science ®Google Scholar
• Romano MR, Parolini B, Allegrini D, et al. An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study. Acta Ophthalmol. 2019;98:e549–58.
   PubMed Web of Science ®Google Scholar
• Daruich A, Matet A, Marchionno L, et al. Acute central serous chorioretinopathy: factors influencing episode duration. Retina. 2017;37(10):1905–1915. doi:10.1097/IAE.0000000000001443
   PubMed Web of Science ®Google Scholar
• Parajuli A, Joshi P. Factors influencing the episode duration and the anatomical and functional outcome in cases of acute central serous chorioretinopathy. BMJ Open Ophthalmol. 2020;5(1):e000540. doi:10.1136/bmjophth-2020-000540
   PubMed Web of Science ®Google Scholar
• Suwal B, Khadka D, Shrestha A, et al. Baseline predictive factors of visual outcome and persistence of subretinal fluid based on morphologic changes in spectral domain optical coherence tomography in patients with idiopathic central serous chorioretinopathy. Clin Ophthalmol. 2019;13:2439–2444. doi:10.2147/OPTH.S233273
   PubMed Web of Science ®Google Scholar
• Greenblatt HK, Greenblatt DJ. Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol. 2014;54(12):1321–1329. doi:10.1002/jcph.400
   PubMed Web of Science ®Google Scholar
• Banankhah PS, Garnick KA, Greenblatt DJ. Ketoconazole-associated liver injury in drug-drug interaction studies in healthy volunteers. J Clin Pharmacol. 2016;56(10):1196–1202. doi:10.1002/jcph.711
   PubMed Web of Science ®Google Scholar
• Wu CY, Riangwiwat T, Rattanawong P, et al. Association of obstructive sleep apnea with central serous chorioretinopathy and choroidal thickness: a systematic review and meta-analysis. Retina. 2018;38(9):1642–1651. doi:10.1097/IAE.0000000000002117
   PubMed Web of Science ®Google Scholar
• Pan CK, Vail D, Bhattacharya J, et al. The effect of obstructive sleep apnea on absolute risk of central serous chorioretinopathy. Am J Ophthalmol. 2020;218:148–155. doi:10.1016/j.ajo.2020.05.040
   PubMed Web of Science ®Google Scholar
• Chopra S, Rathore A, Younas H, et al. Obstructive sleep apnea dynamically increases nocturnal plasma free fatty acids, glucose, and cortisol during sleep. J Clin Endocrinol Metab. 2017;102(9):3172–3181. doi:10.1210/jc.2017-00619
   PubMed Web of Science ®Google Scholar
• Kritikou I, Basta M, Vgontzas AN, et al. Sleep apnoea and the hypothalamic-pituitary-adrenal axis in men and women: effects of continuous positive airway pressure. Eur Respir J. 2016;47(2):531–540. doi:10.1183/13993003.00319-2015
   PubMed Web of Science ®Google Scholar